A Pilot Study of Synbiotics in Adults With Depressive Symptoms
Launched by GENIEBIOME LIMITED · Mar 25, 2025
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special combination of probiotics and prebiotics, known as a synbiotic formula (called MQU10), can help improve mood and overall well-being in adults experiencing mild to moderate symptoms of depression. The study aims to see if this formula can make a positive difference for those who may be feeling down but do not have severe depression.
To participate, individuals need to be at least 18 years old and have a specific score on a depression questionnaire that indicates mild to moderate symptoms. However, some people won't be eligible, such as those with a history of serious mental health issues or certain medical conditions. Participants will complete self-report questionnaires and will need to understand and sign a consent form before joining. This study is not yet recruiting, but it represents an exciting opportunity to explore new ways to support mental health through diet and gut health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals aged 18 or above
- • Patient Health Questionnaire-9 (PHQ-9) score between 5 to 14
- • Literate and can complete the self-report questionnaires
- • Able to understand the consent and sign the informed consent form
- Exclusion Criteria:
- • Current diagnosis of substance abuse or dependence;
- • A current or past history of bipolar disorder, manic or hypomanic episodes, schizophrenia, personality disorder, posttraumatic stress disorder (PTSD), intellectual disability, neurodegenerative disorders (e. g, Parkinson's disease) or organic mental disorder
- • Requiring immediate psychiatric care (e. g, imminently suicidal subjects) or have attempted suicide in the past 3 months
- • Use of antipsychotics, antidepressants or sedatives, unless on a stable dose in the last 4 weeks
- • History of severe organ failure, renal failure on dialysis, HIV infection
- • Active malignancy within 5 years
- • History of major surgery on the gastrointestinal tract, except cholecystectomy and appendectomy in the past 5 years
- • Night shift work
- • History of antibiotic use within 4 weeks
- • History of allergy to probiotics or lactose leading to a severe allergic reaction
- • Known pregnancy or lactating
About Geniebiome Limited
Geniebiome Limited is a pioneering clinical trial sponsor specializing in innovative biotechnological solutions aimed at advancing personalized medicine. With a focus on harnessing genomic and microbiome data, the company conducts rigorous clinical trials to evaluate novel therapeutic interventions and diagnostic tools. Committed to scientific excellence and ethical standards, Geniebiome collaborates with leading research institutions and healthcare providers to drive transformative discoveries that enhance patient outcomes and improve healthcare practices globally. By leveraging cutting-edge technology and a multidisciplinary approach, Geniebiome Limited strives to redefine the landscape of precision healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Jessica Ching, PhD
Study Director
GenieBiome Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported